EUCTR2006-004055-38-DE进行中（未招募）不适用
A Phase II Clinical Study to Compare the Efficacy and Safety of Three Doses of Topical Glyceryl Trinitrate (GTN) to Placebo in Subjects with Mild and/or Moderate Erectile Dysfunction (ED)
Futura Medical Developments (FMD)0 个研究点目标入组 272 人开始时间: 2007年1月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 272
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1.Aged between 18 and 65 years of age.
- •2.Males with mild and/or moderate ED for more than 6 months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
- •3.IIEF-EF score in the range of 11 to 25 inclusive, denoting mild and/or moderate ED at screening.
- •4.The subject must make at least four attempts at sexual intercourse (according to the question in the screening phase diary: Was sexual activity initiated with the intention of intercourse?”) on four separate days during the 4 weeks of the treatment-free run-in period.
- •5.50% or more of the attempts during the 4 week run-in period must be unsuccessful, according to the following questions from the screening phase diary [at least one question should be answered No]: Were you able to achieve at least some erection (some enlargement of the penis)?”, Were you able to insert your penis into your partner’s vagina?” and Did your erection last long enough for you to have successful intercourse?.
- •6.Stable monogamous heterosexual relationship for more than 6 months prior to screening.
- •7.Reproduction and Contraception (at least one of the following criteria must apply):
- •a)Sterile male subjects documented by bilateral vasectomy, bilateral orchiectomy, or azoospermia prior to the subject’s entry into the study, OR
- •b)Female partners of study subjects that are of child bearing potential that are practicing a satisfactory method of contraception for at least 3 months prior to screening:
- •- oral contraceptive, either combined or progestogen alone OR
- •- injectable progestogen OR
- •- implants of levonorgestrel OR
- •- estrogenic vaginal ring OR
- •- percutaneous contraceptive patches OR
- •- intrauterine device (IUD) or intrauterine system (IUS) OR
- •- double barrier method (condom or occlusive cap [diaphragm or cervical vault caps] plus spermicidal agent [foam, gel, film, cream, suppository]).
- •Additionally, a negative result to a human chorionic gonadotropin (HCG) urine pregnancy test performed at home must be obtained by the female partner of the study subject at the beginning of each treatment phase, OR
- •c)Female partners of study subjects that are post-menopausal, as defined as >45 years old, and greater than 1 year since their last menstrual period, in the absence of hormone replacement therapy, OR
- •d)Female partners who are medically proven to be infertile even in the absence of contraception.
- •8.Understands and is willing, able and likely to comply with all study procedures and restrictions.
- •9.Subject and his partner demonstrate understanding of the study and willingness to participate as evidenced by voluntary written informed consents and have received signed and dated copies of the informed consent forms.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •Previous or Current Medical Conditions
- •1.Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study.
- •2.Presence of penile anatomical abnormalities (e.g., phimosis, penile fibrosis or Peyronie’s disease) that, in the opinion of the Investigator, would significantly impair sexual performance.
- •3.Primary hypoactive sexual desire.
- •4.Spinal cord injury.
- •5.History of any pelvic surgery (prostatectomy, colon surgery).
- •6.A history of priapism.
- •7.Clinically significant chronic haematological disease which may lead to priapism such as sickle cell anaemia, multiple myeloma or leukaemia.
- •8.Any underlying cardiovascular condition including unstable angina pectoris that would preclude sexual activity.
- •9.History of myocardial infarction, stroke, hypertrophic obstructive cardiomyopathy, aortic stenosis, cardiac tamponade, constrictive pericarditis, mitral stenosis or any life-threatening arrhythmia within the prior 6 months.
- •10.Uncontrolled atrial fibrillation/flutter (ventricular response rate ? 100 bpm) at the screening visit (Visit 1).
- •11.Resting hypotension (a resting systolic blood pressure of <90 mmHg) or hypertension (a resting systolic blood pressure >170 mmHg or a resting diastolic blood pressure >110 mmHg).
- •12.Symptomatic postural hypotension within 6 months of Screening.
- •13.History of malignancy within the past 5 years.
- •14.Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- •15.Male subjects whose female partner is breastfeeding or plans to breastfeed at any time during the study.
- •Concomitant Medications
- •16.Subjects who are taking nitrates or nitric oxide donors.
- •17.Subjects who are taking anti-androgens.
- •18.Use of any treatment for ED in the past, including but not limited to oral ED medications, vacuum devices, intracavernosal injections, penile prosthesis, urethral suppositories.
- •19.Use of phosphodiesterase-5 inhibitors such as sildenafil, vardenafil or tadalafil is strictly prohibited during the course of the study.
- •Abnormal Laboratory Values
- •20.Subjects who have a serum total testosterone level below the lower limit of normal according to the range of the testing laboratory.
- •Other exclusion criteria
- •21.Subjects who are illiterate or unable to understand the questionnaires or the Subject Diary.
- •22.Subjects who are unwilling or unable to complete the Subject Diary.
- •23.Unwillingness of the subject to make 4 attempts at sexual intercourse on four separate days during the treatment-free baseline period.
- •24.Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures.
- •25.Inability to satisfactorily use the Del Pouch® to apply study medication.
- •26.Clinical Study/Experimental Medication
- •a.Participation in another clinical study or receipt of an investigational drug (including placebo) less than 3 months prior to the screening visit (Visit 1).
- •b.Previous participation in this study.
- •27.An employee or a close family member of either FMD or SSL.
- •28. An employee of the study site or a close family member of an employee at the study site.
研究者
相似试验
进行中（未招募）
不适用
Study to compare the effectiveness of Lotion and Calendula Cream versus Chamomile Cream in an attempt to prevent Skin Reactions in patients with Breast Cancerradio dermatitisBreast neoplasmsegmental mastectomyC04.588.180E04.466.701C17.800.174.826RBR-877t2wHospital de Amor de Barretos
已完成
2 期
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
已完成
2 期
enalidomide and 5azacitidine treatment versus 5azacitidine alone in patients with the blood cancers myelodysplastic syndrome or acute myeloid leukaemiaMyelodysplastic syndromes (MDS)Low marrow blast count acute myeloid leukaemia (AML)Blood - Haematological diseasesCancer - Leukaemia - Acute leukaemiaACTRN12610000271000Australasian Leukaemia and Lymphoma Group160
进行中（未招募）
1 期
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)Huntington's diseaseMedDRA version: 18.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-005112-42-FRINSERM50
已完成
2 期
A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (HD)Huntington's Diseaseneurodegenerative movement disorder1002929910028037NL-OMON43815The French National Institute of Health and Medical Research (Inserm)50